5313-35-9

Basic information

• Product Name: 2-methyl-1H-imidazole-4,5-dicarboxylic acid
• Synonyms: 2-methyl-1H-imidazole-4,5-dicarboxylic acid
• CAS NO: 5313-35-9
• Molecular Formula: C₆H₆N₂O₄
• Molecular Weight: 170.12284
• EINECS: 226-170-8
• Mol File: 5313-35-9.mol
• Article Data: 8

Chemical Properties

• Melting Point: 263-265 °C
• Boiling Point: 606.2 °C at 760 mmHg
• Flash Point: 320.4 °C
• Appearance: /
• Density: 1.662 g/cm³
• Vapor Pressure: 1.52E-15mmHg at 25°C
• Refractive Index: 1.653
• PKA: 0.66±0.10(Predicted)
• CAS DataBase Reference: 2-methyl-1H-imidazole-4,5-dicarboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-methyl-1H-imidazole-4,5-dicarboxylic acid(5313-35-9)
• EPA Substance Registry System: 2-methyl-1H-imidazole-4,5-dicarboxylic acid(5313-35-9)

Safety Data

• Hazardous Substances Data: 5313-35-9(Hazardous Substances Data)

Usage

General Description

2-methyl-1H-imidazole-4,5-dicarboxylic acid is a chemical compound with molecular formula C6H6N2O4. It is a derivative of imidazole and dicarboxylic acid, and contains a methyl group at the 2-position of the imidazole ring. 2-methyl-1H-imidazole-4,5-dicarboxylic acid has unique properties that make it useful in various applications, including as a research tool in biochemistry and pharmaceuticals. It has been studied for its potential use as a building block in the synthesis of novel biologically active compounds, and as a potential drug target for certain diseases. Additionally, it has been investigated for its potential as a corrosion inhibitor and in the development of new materials. Continuing research on 2-methyl-1H-imidazole-4,5-dicarboxylic acid may lead to further understanding of its potential applications and benefits in various industries.

InChI:InChI=1/C6H6N2O4/c1-2-7-3(5(9)10)4(8-2)6(11)12/h1H3,(H,7,8)(H,9,10)(H,11,12)

Upstream product

• 615-15-6 2-Methyl-1H-benzimidazole 
• 75-07-0 acetaldehyde 
• 610-20-8 di-O-nitro-tartaric acid 
• 40056-53-9 2-methyl-1H-imidazole-4,5-dicarbonitrile 
• 13171-63-6 L_g-tartaric acid-dinitrate 
• 853791-97-6 6-hydroxy-2-methyl-1⁽³⁾H-benzimidazole-4-carboxylic acid 

Downstream Products

• 69579-46-0 5-chlorocarbonyl-2-methyl-1(3)H-imidazole-4-carboxylic acid 
• 693-98-1 2-methylimidazole 

Relevant articles and documents

Fluorescent-based solid sensor for HSO4- in water

In this report, we have shown that the encapsulation of the terbium 2-methylimidazole-4,5-dicarboxylic acid complex into inorganic host tetraethoxysilance is considered to be an efficient way for the design of anion sensors. Strong green emission still can be observed when it disperses in pure water. It was found that the luminescence of hybrid material was selectively turned off rapidly (1 s) by hydrogen sulfate compared with the addition of different anions such as F-, Cl-, Br- and I-. Thin film was successfully prepared and also could be a promising tool for recognizing HSO4-.

Influence of Oxidation Conditions on the Yield of 2-Substituted Imidazole-4,5-dicarboxylic Acids

Conditions were found which allow 2-alkyl-substituted imidazole-4,5-dicarboxylic acids to be synthesized in preparative quantities by the oxidation of 2-alkylbenzimidazoles with hydrogen peroxide. It was shown that optimal results can be obtained at the concentration of 2-alkylimidazole in sulfuric acid of 1 M and the hydrogen peroxide: 2-alkylbenzimidazole molar ratio of 11: 1. Oxidation under these conditions results in higher yields of the target 2-alkylimidazole-4,5-dicarboxylic acids, including those with a branched alkyl group.

JAK-2 MODULATORS AND METHODS OF USE

This invention relates to the field of protein tyrosine kinases and inhibitors thereof. In particular, the invention relates to inhibitors of JAK-2, pharmaceutical compositions of the compounds for inhibiting JAK-2, methods of inhibiting JAK-2 in a cell, comprising contacting a cell in which inhibition of JAK-2 is desired with a compound or pharmaceutical composition comprising a compound according to the invention. The also comprises methods of treating a disease or condition that involves JAK-2 comprising administering to a patient a pharmaceutical composition comprising a compound according to the invention